Peter Corry
Concepts (220)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperthermia, Induced | 9 | 2012 | 108 | 1.380 |
Why?
| Radiotherapy, Intensity-Modulated | 6 | 2017 | 170 | 1.010 |
Why?
| Antioxidants | 2 | 2020 | 297 | 0.940 |
Why?
| Radiotherapy Planning, Computer-Assisted | 8 | 2017 | 245 | 0.870 |
Why?
| Tomography, Spiral Computed | 5 | 2017 | 56 | 0.770 |
Why?
| Radiometry | 6 | 2017 | 125 | 0.760 |
Why?
| Abdomen | 2 | 2011 | 84 | 0.750 |
Why?
| Radiation-Protective Agents | 3 | 2020 | 116 | 0.720 |
Why?
| Heart | 4 | 2013 | 361 | 0.650 |
Why?
| Oxygen | 3 | 2012 | 361 | 0.630 |
Why?
| Radiotherapy, Image-Guided | 3 | 2016 | 25 | 0.620 |
Why?
| Neoplasms | 7 | 2016 | 1322 | 0.610 |
Why?
| Pneumonia, Viral | 1 | 2020 | 184 | 0.580 |
Why?
| Coronavirus Infections | 1 | 2020 | 192 | 0.570 |
Why?
| Organ Sparing Treatments | 2 | 2016 | 54 | 0.540 |
Why?
| Radiotherapy | 3 | 2012 | 137 | 0.530 |
Why?
| Mammary Neoplasms, Experimental | 3 | 2012 | 135 | 0.510 |
Why?
| Pandemics | 1 | 2020 | 594 | 0.510 |
Why?
| Organs at Risk | 3 | 2016 | 70 | 0.470 |
Why?
| Radiation Injuries, Experimental | 2 | 2013 | 105 | 0.460 |
Why?
| Head and Neck Neoplasms | 3 | 2017 | 336 | 0.450 |
Why?
| Galectin 1 | 1 | 2012 | 21 | 0.420 |
Why?
| Radiation Injuries | 3 | 2013 | 153 | 0.420 |
Why?
| Blood Vessels | 1 | 2012 | 78 | 0.410 |
Why?
| Peptides | 2 | 2012 | 276 | 0.400 |
Why?
| Molecular Targeted Therapy | 1 | 2012 | 128 | 0.400 |
Why?
| Brain Neoplasms | 2 | 2012 | 285 | 0.390 |
Why?
| Radiosurgery | 1 | 2012 | 122 | 0.380 |
Why?
| Bone and Bones | 2 | 2011 | 515 | 0.380 |
Why?
| Myocardium | 4 | 2014 | 443 | 0.370 |
Why?
| Animals | 19 | 2021 | 14409 | 0.360 |
Why?
| Acetylcysteine | 1 | 2010 | 118 | 0.360 |
Why?
| Carcinoma, Squamous Cell | 2 | 2012 | 385 | 0.350 |
Why?
| Ultrasonic Therapy | 2 | 2008 | 40 | 0.340 |
Why?
| Image Processing, Computer-Assisted | 3 | 2017 | 256 | 0.340 |
Why?
| Cerebellar Neoplasms | 2 | 2009 | 23 | 0.340 |
Why?
| Cranial Irradiation | 2 | 2009 | 24 | 0.340 |
Why?
| Bone Density | 1 | 2011 | 416 | 0.340 |
Why?
| Medulloblastoma | 1 | 2008 | 17 | 0.320 |
Why?
| Oxygen Consumption | 1 | 2009 | 223 | 0.310 |
Why?
| Radiotherapy Dosage | 7 | 2017 | 245 | 0.310 |
Why?
| Mice | 9 | 2021 | 6428 | 0.290 |
Why?
| Combined Modality Therapy | 6 | 2012 | 693 | 0.280 |
Why?
| Radiobiology | 1 | 2005 | 20 | 0.270 |
Why?
| Heat-Shock Response | 1 | 2005 | 29 | 0.270 |
Why?
| Heat-Shock Proteins | 1 | 2005 | 87 | 0.260 |
Why?
| Whole-Body Irradiation | 2 | 2020 | 161 | 0.260 |
Why?
| Medicine | 1 | 2005 | 58 | 0.260 |
Why?
| Dose-Response Relationship, Radiation | 4 | 2012 | 204 | 0.230 |
Why?
| Brain | 1 | 2012 | 1392 | 0.230 |
Why?
| Radiation Dosage | 3 | 2008 | 170 | 0.220 |
Why?
| Radiotherapy, Conformal | 2 | 2016 | 55 | 0.220 |
Why?
| Tocotrienols | 2 | 2013 | 42 | 0.220 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 15 | 0.200 |
Why?
| Rats | 7 | 2021 | 3419 | 0.190 |
Why?
| Angiogenesis Inhibitors | 2 | 2012 | 203 | 0.180 |
Why?
| Humans | 21 | 2021 | 54391 | 0.180 |
Why?
| Neovascularization, Pathologic | 2 | 2012 | 168 | 0.180 |
Why?
| Models, Biological | 3 | 2016 | 825 | 0.170 |
Why?
| Hot Temperature | 3 | 2012 | 199 | 0.170 |
Why?
| MicroRNAs | 1 | 2021 | 386 | 0.150 |
Why?
| Radiation Protection | 2 | 2016 | 55 | 0.140 |
Why?
| Cell Line, Tumor | 4 | 2012 | 1551 | 0.130 |
Why?
| Mice, Inbred C57BL | 2 | 2011 | 2001 | 0.130 |
Why?
| Phantoms, Imaging | 3 | 2011 | 126 | 0.120 |
Why?
| Equipment Design | 2 | 2012 | 318 | 0.120 |
Why?
| Pentoxifylline | 1 | 2013 | 19 | 0.120 |
Why?
| Immunohistochemistry | 2 | 2013 | 1090 | 0.110 |
Why?
| Monte Carlo Method | 1 | 2013 | 99 | 0.110 |
Why?
| Radiography | 3 | 2009 | 526 | 0.110 |
Why?
| Kininogens | 1 | 2012 | 4 | 0.110 |
Why?
| Kallikrein-Kinin System | 1 | 2012 | 4 | 0.110 |
Why?
| Ablation Techniques | 1 | 2012 | 25 | 0.110 |
Why?
| Prostatic Neoplasms | 1 | 2017 | 421 | 0.110 |
Why?
| Tumor Burden | 2 | 2010 | 141 | 0.110 |
Why?
| Radiation Tolerance | 1 | 2013 | 87 | 0.110 |
Why?
| Bystander Effect | 1 | 2012 | 22 | 0.110 |
Why?
| Time Factors | 4 | 2014 | 3210 | 0.110 |
Why?
| Cell Hypoxia | 1 | 2012 | 87 | 0.100 |
Why?
| Myocarditis | 1 | 2012 | 45 | 0.100 |
Why?
| Male | 10 | 2021 | 27347 | 0.100 |
Why?
| Models, Theoretical | 1 | 2012 | 184 | 0.100 |
Why?
| Computer Simulation | 4 | 2016 | 332 | 0.100 |
Why?
| Organ Specificity | 1 | 2011 | 126 | 0.100 |
Why?
| Cell Survival | 2 | 2012 | 657 | 0.100 |
Why?
| Cell Proliferation | 2 | 2012 | 1097 | 0.100 |
Why?
| Lung Neoplasms | 1 | 2017 | 643 | 0.090 |
Why?
| Leukocyte Count | 1 | 2010 | 77 | 0.090 |
Why?
| Malformations of Cortical Development | 1 | 2009 | 4 | 0.090 |
Why?
| Tubulin | 1 | 2009 | 28 | 0.090 |
Why?
| Mitochondria | 1 | 2014 | 490 | 0.090 |
Why?
| Optic Nerve Diseases | 1 | 2009 | 27 | 0.090 |
Why?
| Taxoids | 1 | 2009 | 45 | 0.090 |
Why?
| Radiation Pneumonitis | 1 | 2009 | 9 | 0.090 |
Why?
| Carboplatin | 1 | 2009 | 63 | 0.090 |
Why?
| Fluorouracil | 1 | 2009 | 61 | 0.090 |
Why?
| Disease Progression | 1 | 2012 | 915 | 0.090 |
Why?
| Spinal Neoplasms | 1 | 2009 | 32 | 0.080 |
Why?
| Body Weight | 1 | 2011 | 578 | 0.080 |
Why?
| Paclitaxel | 1 | 2009 | 103 | 0.080 |
Why?
| Necrosis | 1 | 2009 | 208 | 0.080 |
Why?
| Signal Transduction | 2 | 2013 | 1752 | 0.080 |
Why?
| History, 20th Century | 1 | 2009 | 114 | 0.080 |
Why?
| Microscopy, Fluorescence | 1 | 2009 | 198 | 0.080 |
Why?
| Osteogenesis | 1 | 2011 | 377 | 0.080 |
Why?
| Bone Marrow | 1 | 2010 | 414 | 0.080 |
Why?
| Weight Loss | 1 | 2010 | 271 | 0.080 |
Why?
| Radiotherapy, Computer-Assisted | 1 | 2007 | 16 | 0.080 |
Why?
| Reactive Oxygen Species | 1 | 2010 | 491 | 0.080 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 868 | 0.080 |
Why?
| Skull | 1 | 2007 | 79 | 0.080 |
Why?
| Central Nervous System Neoplasms | 1 | 2007 | 57 | 0.070 |
Why?
| Cisplatin | 1 | 2009 | 351 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2009 | 2390 | 0.070 |
Why?
| Spine | 1 | 2007 | 112 | 0.070 |
Why?
| Particle Accelerators | 2 | 2017 | 50 | 0.070 |
Why?
| Swine | 3 | 2012 | 430 | 0.070 |
Why?
| Rats, Sprague-Dawley | 3 | 2014 | 1664 | 0.070 |
Why?
| Cell Death | 1 | 2005 | 223 | 0.060 |
Why?
| Temperature | 1 | 2005 | 177 | 0.060 |
Why?
| Retrospective Studies | 3 | 2012 | 6459 | 0.060 |
Why?
| Treatment Outcome | 2 | 2012 | 5612 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 55 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 55 | 0.060 |
Why?
| Antigens, Differentiation, Myelomonocytic | 2 | 2013 | 46 | 0.060 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1060 | 0.060 |
Why?
| Mutation | 1 | 2009 | 1504 | 0.060 |
Why?
| Cell Line | 1 | 2005 | 1152 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 6 | 0.050 |
Why?
| Aged | 2 | 2021 | 10060 | 0.050 |
Why?
| Antigens, CD | 2 | 2013 | 242 | 0.050 |
Why?
| Cricetinae | 1 | 2021 | 209 | 0.050 |
Why?
| Glycolysis | 1 | 2021 | 73 | 0.050 |
Why?
| Phosphorylation | 2 | 2013 | 613 | 0.050 |
Why?
| ROC Curve | 1 | 2021 | 259 | 0.050 |
Why?
| Middle Aged | 2 | 2021 | 13082 | 0.050 |
Why?
| Antiviral Agents | 1 | 2021 | 188 | 0.050 |
Why?
| Adult | 2 | 2021 | 14207 | 0.040 |
Why?
| Rabbits | 2 | 2010 | 425 | 0.040 |
Why?
| Proteomics | 1 | 2021 | 343 | 0.040 |
Why?
| Gene Expression | 2 | 2012 | 664 | 0.040 |
Why?
| Female | 6 | 2021 | 28471 | 0.040 |
Why?
| Inflammation | 1 | 2021 | 678 | 0.040 |
Why?
| X-Rays | 1 | 2016 | 57 | 0.040 |
Why?
| Cone-Beam Computed Tomography | 1 | 2016 | 34 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2009 | 922 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 2021 | 1063 | 0.030 |
Why?
| Child, Preschool | 3 | 2009 | 4158 | 0.030 |
Why?
| Multiple Myeloma | 1 | 2010 | 3049 | 0.030 |
Why?
| Reproducibility of Results | 2 | 2009 | 1301 | 0.030 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 23 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 48 | 0.030 |
Why?
| Cell Respiration | 1 | 2014 | 51 | 0.030 |
Why?
| bcl-2-Associated X Protein | 1 | 2014 | 73 | 0.030 |
Why?
| Protein Kinase C-alpha | 1 | 2013 | 11 | 0.030 |
Why?
| Aged, 80 and over | 1 | 2021 | 3431 | 0.030 |
Why?
| Protein Conformation | 1 | 2014 | 226 | 0.030 |
Why?
| Software | 1 | 2016 | 297 | 0.030 |
Why?
| Mast Cells | 1 | 2013 | 64 | 0.030 |
Why?
| Cell Count | 1 | 2013 | 181 | 0.030 |
Why?
| Skin Temperature | 1 | 2012 | 19 | 0.030 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 158 | 0.030 |
Why?
| Drug Interactions | 1 | 2013 | 206 | 0.030 |
Why?
| Mitochondrial Swelling | 1 | 2012 | 5 | 0.030 |
Why?
| Rats, Inbred BN | 1 | 2012 | 21 | 0.030 |
Why?
| Receptor, Bradykinin B2 | 1 | 2012 | 9 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 176 | 0.030 |
Why?
| Models, Animal | 1 | 2013 | 255 | 0.030 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.030 |
Why?
| Administration, Oral | 1 | 2013 | 461 | 0.030 |
Why?
| Up-Regulation | 1 | 2014 | 509 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2012 | 133 | 0.030 |
Why?
| Child | 3 | 2009 | 7368 | 0.030 |
Why?
| Neck | 1 | 2012 | 116 | 0.030 |
Why?
| Computer-Aided Design | 1 | 2011 | 21 | 0.030 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 49 | 0.030 |
Why?
| Fibrosarcoma | 1 | 2011 | 13 | 0.030 |
Why?
| Partial Pressure | 1 | 2011 | 17 | 0.020 |
Why?
| Endothelial Cells | 1 | 2013 | 294 | 0.020 |
Why?
| Heart Ventricles | 1 | 2013 | 271 | 0.020 |
Why?
| Blotting, Western | 1 | 2012 | 684 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 674 | 0.020 |
Why?
| Burns | 1 | 2012 | 170 | 0.020 |
Why?
| Bone Transplantation | 1 | 2010 | 55 | 0.020 |
Why?
| Consanguinity | 1 | 2009 | 15 | 0.020 |
Why?
| Radiation-Sensitizing Agents | 1 | 2010 | 55 | 0.020 |
Why?
| Pakistan | 1 | 2009 | 24 | 0.020 |
Why?
| Genes, Recessive | 1 | 2009 | 18 | 0.020 |
Why?
| DNA Damage | 1 | 2012 | 357 | 0.020 |
Why?
| Feasibility Studies | 1 | 2011 | 398 | 0.020 |
Why?
| Nuclear Family | 1 | 2009 | 14 | 0.020 |
Why?
| Cell Transformation, Neoplastic | 1 | 2011 | 200 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 195 | 0.020 |
Why?
| Protein Isoforms | 1 | 2009 | 124 | 0.020 |
Why?
| Pedigree | 1 | 2009 | 146 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 82 | 0.020 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2011 | 192 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Syndrome | 1 | 2009 | 253 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2009 | 115 | 0.020 |
Why?
| Base Sequence | 1 | 2009 | 719 | 0.020 |
Why?
| Genetic Variation | 1 | 2009 | 253 | 0.020 |
Why?
| Metals | 1 | 2008 | 44 | 0.020 |
Why?
| Acute Disease | 1 | 2009 | 403 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2009 | 980 | 0.020 |
Why?
| Apoptosis | 1 | 2014 | 1302 | 0.020 |
Why?
| Lung | 1 | 2011 | 508 | 0.020 |
Why?
| Algorithms | 1 | 2011 | 697 | 0.020 |
Why?
| Proteins | 1 | 2010 | 376 | 0.020 |
Why?
| Breast Neoplasms | 1 | 2016 | 1249 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2009 | 552 | 0.020 |
Why?
| Oxidative Stress | 1 | 2012 | 958 | 0.020 |
Why?
| Survival Rate | 1 | 2009 | 954 | 0.020 |
Why?
| Adolescent | 2 | 2009 | 6900 | 0.020 |
Why?
| Skin | 1 | 2009 | 469 | 0.020 |
Why?
| Kidney | 1 | 2011 | 822 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 1082 | 0.020 |
Why?
| Liver | 1 | 2011 | 1226 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2008 | 1222 | 0.010 |
Why?
| Young Adult | 1 | 2009 | 4318 | 0.010 |
Why?
|
|
Corry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|